×
For best experience we recommend to activate Javascript in your browser.
Recombinant Mesothelin (Amatuximab Biosimilar) antibody
The Chimeric Chimeric anti-Mesothelin (Amatuximab Biosimilar) antibody is suitable to detect Mesothelin (Amatuximab Biosimilar) in samples from Human.
Catalog No. ABIN7597501
$401.14
Plus shipping costs $50.00, if applicable $20.00 dry ice
1 mg ABIN7598439
100 μg ABIN7597501
1 mg ABIN7598439
100 μg ABIN7597501
Delivery in 12 to 14 Business Days
Quick Overview for Recombinant Mesothelin (Amatuximab Biosimilar) antibody (ABIN7597501)
Target
Mesothelin (Amatuximab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for Mesothelin (Amatuximab Biosimilar) antibodies
Chimeric
Clonality
All clonalities for Mesothelin (Amatuximab Biosimilar) antibodies
Chimeric
Conjugate
All conjugates for Mesothelin (Amatuximab Biosimilar) antibodies
This Mesothelin (Amatuximab Biosimilar) antibody is un-conjugated
Application
Please inquire
Grade
Research Grade
Product Details anti-Mesothelin (Amatuximab Biosimilar) Antibody
(hide)
Expression System
Mammalian cells
Purpose
Research Grade Amatuximab Biosimilar Antibody
Specificity
CAK1 antigen, Mesothelin, MSLN, Pre-pro-megakaryocyte-potentiating factor, MPF
Purification
Protein A or G purified from cell culture supernatant.
Purity
>95 % by SDS-PAGE.
Isotype
IgG1 kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1.77 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target Details for Mesothelin (Amatuximab Biosimilar)
(hide)
Target
Mesothelin (Amatuximab Biosimilar)
Alternative Name
Amatuximab Biosimilar
Target Type
Biosimilar
Background
CAK1 antigen, Mesothelin, MSLN, Pre-pro-megakaryocyte-potentiating factor, MPF
UniProt
Q13421
CAS-No
931402-35-6
Recently viewed
(hide)
Chat with us , powered by LiveChat